Tirzepatide
SURMOUNT-1
Eli Lilly · Phase 3 · Completed · Enrollment 2539
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Placebo | Obesity, no T2D | n/r | 72 | ITT | -3.1% at week 72 |
| 5 mg Tirzepatide | Obesity, no T2D | 5 mg | 72 | ITT | -15% at week 72 |
| 10 mg Tirzepatide | Obesity, no T2D | 10 mg | 72 | ITT | -19.5% at week 72 |
| 15 mg Tirzepatide | Obesity, no T2D | 15 mg | 72 | ITT | -20.9% at week 72 |